Ferro-Flores G - Search Results

1

Engineered rHDL Nanoparticles as a Suitable Platform for Theranostic Applications.

Aranda-Lara L, Isaac-Olivé K, Ocampo-García B, Ferro-Flores G, González-Romero C, Mercado-López A, García-Marín R, Santos-Cuevas C, Estrada JA, Morales-Avila E. Aranda-Lara L, et al. Among authors: ferro flores g. Molecules. 2022 Oct 19;27(20):7046. doi: 10.3390/molecules27207046. Molecules. 2022. PMID: 36296638 Free PMC article.

2

[Radiopharmacokinetic and gammagraphic studies for calculating personalized dosimetry].

Arteaga de Murphy C, Pedraza-López M, Ferro-Flores G, Montoya-Molina CE, Meléndez-Alafort L. Arteaga de Murphy C, et al. Rev Invest Clin. 2001 May-Jun;53(3):228-34. Rev Invest Clin. 2001. PMID: 11496710 Spanish.

3

Cytotoxic and genotoxic effect of the [166Dy]Dy/166Ho-EDTMP in vivo generator system in mice.

Pedraza-López M, Ferro-Flores G, Arteaga de Murphy C, Morales-Ramírez P, Piedras-Ross J, Murphy-Stack E, Hernández-Oviedo O. Pedraza-López M, et al. Nucl Med Biol. 2004 Nov;31(8):1079-85. doi: 10.1016/j.nucmedbio.2004.08.010. Nucl Med Biol. 2004. PMID: 15607490

4

Radiopharmacokinetics, renal clearance and dosimetry of 99mTc-MAG3.

Arteaga de Murphy C, Molina-Trinidad E, Meléndez-Alafort L, Ferro-Flores G, Reyes-Herrera L, Sepúlveda-Méndez J, Sandoval-Guzmán B, Hoyo-Vadillo C. Arteaga de Murphy C, et al. Arch Med Res. 1999 Jan-Feb;30(1):49-54. doi: 10.1016/s0188-0128(98)00004-9. Arch Med Res. 1999. PMID: 10071425

5

99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.

Arteaga de Murphy C, Ferro-Flores G, Villanueva-Sanchez O, Murphy-Stack E, Pedraza-López M, Meléndez-Alafort L, Molina-Trinidad E. Arteaga de Murphy C, et al. Int J Pharm. 2002 Feb 21;233(1-2):29-34. doi: 10.1016/s0378-5173(01)00922-x. Int J Pharm. 2002. PMID: 11897407

6

Electrostatic binding with tat and other cationic peptides increases cell accumulation of 99mTc-antisense DNAs without entrapment.

Zhang YM, Liu CB, Liu N, Ferro Flores G, He J, Rusckowski M, Hnatowich DJ. Zhang YM, et al. Mol Imaging Biol. 2003 Jul-Aug;5(4):240-7. doi: 10.1016/s1536-1632(03)00106-9. Mol Imaging Biol. 2003. PMID: 14499139

7

Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits.

González-Vázquez A, Ferro-Flores G, Arteaga de Murphy C, Gutiérrez-García Z. González-Vázquez A, et al. Appl Radiat Isot. 2006 Jul;64(7):792-7. doi: 10.1016/j.apradiso.2006.01.015. Epub 2006 Mar 15. Appl Radiat Isot. 2006. PMID: 16542847

8

Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women.

Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Pichardo-Romero PA. Santos-Cuevas CL, et al. Nucl Med Commun. 2008 Aug;29(8):741-7. doi: 10.1097/MNM.0b013e3282ffb45c. Nucl Med Commun. 2008. PMID: 18753829 Clinical Trial.

9

Gold nanoparticles conjugated to [Tyr3]octreotide peptide.

Surujpaul PP, Gutiérrez-Wing C, Ocampo-García B, Ramírez Fde M, Arteaga de Murphy C, Pedraza-López M, Camacho-López MA, Ferro-Flores G. Surujpaul PP, et al. Biophys Chem. 2008 Dec;138(3):83-90. doi: 10.1016/j.bpc.2008.09.005. Epub 2008 Sep 14. Biophys Chem. 2008. PMID: 18819743

10

Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.

Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Ramírez Fde M, Luna-Gutiérrez MA, Pedraza-López M, García-Becerra R, Ordaz-Rosado D. Santos-Cuevas CL, et al. Int J Pharm. 2009 Jun 22;375(1-2):75-83. doi: 10.1016/j.ijpharm.2009.04.018. Epub 2009 Apr 22. Int J Pharm. 2009. PMID: 19393305

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page